

This Listing of Claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS

Claim 1 (currently amended): A method for diagnosing prostate cancer, the method comprising the step of detecting increased levels of a human endogenous MMTV-like subgroup 2 (HML-2) retrovirus encoded expression product in a patient prostate or blood sample relative to a negative control sample, wherein increased levels of at least 150% are indicative of a diagnosis of prostate cancer.

Claim 2 (previously presented): The method of claim 1 wherein the expression product is an RNA or a polypeptide.

Claim 3 (previously presented): The method of claim 1 wherein the patient sample is a prostate sample.

Claim 4 (previously presented): The method of claim 1 wherein the expression product is an RNA comprising SEQ ID NO:155.

Claim 5 (previously presented): The method of claim 4 wherein the expression product is an RNA comprising SEQ ID NO:5.

Claim 6 (previously presented): The method of claim 4 wherein SEQ ID NO:155 is at the 5' end of the RNA.

Claim 7 (previously presented): The method of claim 2 wherein the RNA comprises  
SEQ ID NO:155 and SEQ ID NO:5.

Claim 8 (canceled)

Claim 9 (previously presented): The method of claim 2 wherein the expression product is  
a polypeptide and wherein the polypeptide is selected from the group consisting of gag, prt,  
pol, env, cORF, and tat.

Claim 10 (previously presented): The method of claim 9 wherein the polypeptide is  
detected using an antibody.

Claims 11-12 (canceled)

Claim 13 (previously presented): The method of claim 2 further comprising the step of  
enriching RNA in the patient sample.

Claim 14 (previously presented): The method of claim 1 wherein the expression product  
is detected using PCR, SDA, SSSR, LCR, TMA or NASBA.

Claim 15 (previously presented): The method of claim 14 wherein the PCR is RT-PCR.

Claims 16-38 (canceled)